Plasma Exosome-Derived Fragile Site-Associated Tumor Suppressor As a Powerful Prognostic Predictor for Patients With Ovarian Cancer. Biomol Biomed 2022, 22 (3), 453-459. https://doi.org/10.17305/bjbms.2021.6404.